FY2025 EPS Estimates for CVRx Reduced by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has revised its FY2025 earnings per share (EPS) estimates for CVRx, lowering the forecast from ($1.97) to ($1.99).
• CVRx reported a quarterly loss of ($0.57) per share, missing the analysts' consensus estimate of ($0.52), but the company achieved revenue of $13.59 million, exceeding expectations.
• Currently, the consensus rating for CVRx is "Moderate Buy" with an average target price of $14.00 per share, amid varying ratings from other analysts.

CVRx, Inc. (NASDAQ:CVRX - Free Report) - Research analysts at Cantor Fitzgerald dropped their FY2025 earnings per share (EPS) estimates for CVRx in a research report issued on Wednesday, August 6th. Cantor Fitzgerald analyst R. Osborn now forecasts that the company will earn ($1.99) per share for the year, down from their previous forecast of ($1.97). Cantor Fitzgerald currently has a "Overweight" rating and a $11.00 target price on the stock. The consensus estimate for CVRx's current full-year earnings is ($1.91) per share. Cantor Fitzgerald also issued estimates for CVRx's FY2026 earnings at ($1.88) EPS.

CVRx (NASDAQ:CVRX - Get Free Report) last issued its quarterly earnings data on Monday, August 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). The business had revenue of $13.59 million during the quarter, compared to the consensus estimate of $13.22 million. CVRx had a negative return on equity of 79.31% and a negative net margin of 95.61%.

Other equities analysts have also recently issued research reports about the stock. JPMorgan Chase & Co. reiterated an "underweight" rating and issued a $7.00 price objective (down previously from $15.00) on shares of CVRx in a research note on Friday, May 9th. Piper Sandler dropped their price objective on CVRx from $20.00 to $12.00 and set an "overweight" rating for the company in a report on Friday, May 9th. Finally, William Blair raised CVRx to a "strong-buy" rating in a research report on Monday, July 7th. One research analyst has rated the stock with a sell rating, five have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $14.00.

CVRx Price Performance

NASDAQ:CVRX opened at $6.94 on Friday. The firm has a 50-day simple moving average of $6.89 and a two-hundred day simple moving average of $9.42. The firm has a market cap of $180.95 million, a P/E ratio of -3.30 and a beta of 1.27. CVRx has a fifty-two week low of $4.30 and a fifty-two week high of $18.55. The company has a debt-to-equity ratio of 0.85, a quick ratio of 13.45 and a current ratio of 11.99.

Hedge Funds Weigh In On CVRx

Several hedge funds and other institutional investors have recently modified their holdings of the company. Larson Financial Group LLC acquired a new stake in CVRx during the 1st quarter valued at $28,000. Tower Research Capital LLC TRC lifted its position in shares of CVRx by 43.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,900 shares of the company's stock worth $49,000 after buying an additional 1,186 shares during the last quarter. GAMMA Investing LLC boosted its holdings in shares of CVRx by 1,469.3% in the 1st quarter. GAMMA Investing LLC now owns 4,598 shares of the company's stock valued at $56,000 after buying an additional 4,305 shares during the period. Quarry LP bought a new position in shares of CVRx during the fourth quarter valued at approximately $69,000. Finally, Whittier Trust Co. acquired a new stake in CVRx in the first quarter worth $73,000. 75.27% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CVRx

In related news, Director Kirk G. Nielsen acquired 10,966 shares of the company's stock in a transaction dated Thursday, May 15th. The stock was bought at an average price of $5.45 per share, with a total value of $59,764.70. Following the purchase, the director directly owned 1,910,134 shares in the company, valued at $10,410,230.30. The trade was a 0.58% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders have purchased a total of 78,666 shares of company stock worth $411,031 in the last quarter. 13.90% of the stock is currently owned by company insiders.

About CVRx

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.